SIGA is a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens.
The Company's common stock trades on NASDAQ under the stock symbol SIGA.
As of October 17, 2011 there were 51,418,518 shares of common stock outstanding.
SIGA's administrative offices are located at 35 East 62nd Street,
New York, NY 10065
and its research and development facilities are located in Corvallis, Oregon.
As of January 31, 2012, the company had 69 full-time employees.
Shares of the Company's common stock can be bought or sold like any other publicly traded stock.
The Company does not offer a direct share purchase plan.
The Company does not currently issue dividends or have a DRIP program.
American Stock Transfer & Trust Company, which may be reached at (718) 921-8293.
The documents that SIGA files with the SEC can be reviewed or downloaded at no charge from our website (see "Financial Information" in the Investor Relations section of http://www.siga.com). The documents can also be obtained at no charge from the SEC website,
http://www.sec.gov.
Any investor questions can be directed to the following individuals at KCSA Strategic Communications:
Todd Fromer,
tfromer@kcsa.com
Phone #: 212-682-6300
The Company's annual report and other financial data can be obtained by contacting KCSA Strategic Communications at 212.682.6300 or by going to
http://www.siga.com/Investor Relations/Financial Information/Printed Materials.
Please submit your question using the form below. * Required fields
shareholder briefcase
investor kit
email alerts
download library
news feeds
Email Page
Print Page
Share this page
delicious
Digg
Facebook
LinkedIn
Twitter
Yahoo! Buzz
show all
hide all